Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria
New England Journal of Medicine2024Vol. 390(17), pp. 1549–1559
Citations Over TimeTop 1% of 2024 papers
Kassoum Kayentao, Aïssata Ongoïba, Anne C Preston, Sara A. Healy, Zonghui Hu, Jeff Skinner, Safiatou Doumbo, Jing Wang, Hamidou Cisse, Didier Doumtabé, Abdrahamane Traoré, Hamadi Traore, Adama Djiguiba, Shanping Li, Mary Peterson, Shinyi Telscher, Azza H. Idris, William C. Adams, Adrian B. McDermott, Sandeep Narpala, Bob C. Lin, Leonid Serebryannyy, Somia P. Hickman, Andrew McDougal, Sandra Vazquez, M.A. REIBER, Judy Stein, Jason G. Gall, Kevin Carlton, Philipp Schwabl, Siriman Traoré, Mamadou Keïta, Amatigué Zéguimé, Adama Ouattara, M’Bouye Doucoure, Amagana Dolo, Sean C. Murphy, Daniel E. Neafsey, Sílvia Portugal, Abdoulaye Djimdé, Boubacar Traoré, Robert A. Seder, Peter D. Crompton
Abstract
Subcutaneous administration of L9LS to children was protective against P. falciparum infection and clinical malaria over a period of 6 months. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT05304611.).
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks(2014)391 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → Ιστορική εξέλιξη της έννοιας του placebo από τα μέσα του 19ου αιώνα μέχρι σήμερα(2006)